JP Morgan Chase’s Epizyme, Inc EPZM Stock Holding History

JP Morgan Chase’s Portfolio EPZM Stock Details EPZM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-63,500	Closed	-$159K	–	7260
2021 Q4	$159K	Hold	63,500	–	–	﹤0.01%	5476
2021 Q3	$325K	Buy	63,500 +33,500	+112%	+$203K	﹤0.01%	4972
2021 Q2	$249K	Hold	30,000	–	–	﹤0.01%	5122
2021 Q1	$261K	Hold	30,000	–	–	﹤0.01%	5038
2020 Q4	$326K	Buy	+30,000	New	+$370K	﹤0.01%	4607
2019 Q3	–	Sell	-40,000	Closed	-$488K	–	6056
2019 Q2	$488K	Sell	40,000 -35,000	-47%	-$450K	﹤0.01%	4249
2019 Q1	$929K	Buy	75,000 +40,000	+114%	+$447K	﹤0.01%	3850
2018 Q4	$216K	Sell	35,000 -5,000	-13%	-$38.2K	﹤0.01%	4569
2018 Q3	$424K	Buy	+40,000	New	+$457K	﹤0.01%	4353

Other funds holding EPZM

Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return

JP Morgan Chase's EPZM Position: Q3 2022 in Review

JP Morgan Chase sold out of Epizyme, Inc (EPZM) in Q3 2022, closing a stake of 5,001 shares — an estimated $7K sold.

JP Morgan Chase first reported a position in EPZM in Q1 2014 and held it in 34 quarters. The position peaked at $15.6M in Q2 2014. 0 funds tracked by Wall St. Rank hold EPZM as of Q3 2022.

JP Morgan Chase reported no remaining Epizyme, Inc position as of Q3 2022 after selling out during the quarter.
JP Morgan Chase sold 5,001 Epizyme, Inc shares in Q3 2022, an estimated $7K.
JP Morgan Chase first reported a position in Epizyme, Inc in Q1 2014 and held it in 34 quarters.
JP Morgan Chase's Epizyme, Inc position peaked at $15.6M in Q2 2014.
0 funds tracked by Wall St. Rank held Epizyme, Inc as of Q3 2022.

Based on JP Morgan Chase's 13F filing for Q3 2022, filed 14 Nov 2022.